Regencell Bioscience Holdings (Regencell Bioscience Holdings) Cash And Cash Equivalents : $1.57 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Regencell Bioscience Holdings's quarterly cash and cash equivalents declined from Jun. 2022 ($6.42 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($1.57 Mil).

Regencell Bioscience Holdings's annual cash and cash equivalents increased from Jun. 2021 ($0.06 Mil) to Jun. 2022 ($6.42 Mil) but then declined from Jun. 2022 ($6.42 Mil) to Jun. 2023 ($1.57 Mil).

Regencell Bioscience Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Regencell Bioscience Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

0.24

0.39

0.06

6.42

1.57

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial				0.06	-	6.42	-	1.57

Regencell Bioscience Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Regencell Bioscience Holdings (NAS:RGC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Regencell Bioscience Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.